Tito Fojo on Muck Rack

Tito Fojo

New York
As seen in: Nature, Memory Studies, ScienceDirect, The Oncologist, JAMA (The Journal of the American Medical Association), JAMA Oncology, The Lancet, The Journal of Clinical Investigation
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Tito

Contact Tito, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Skimming the Median and the Problem of Exaggerated Survival Gains

|
By Tito Fojo
| JAMA Oncology
How to best assess the significance, worth, and meaning of trial results remains an unsolved problem. Kaplan-Meier plots remain a valuable tool for assessing treatment efficacy in clinical trials, especially regarding time-to-event outcomes; however, they should be used in conjunction with other assessments for a comprehensive evaluation of treatment risks and benefits.
Open in Who Shared Issue with article?

Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitors and Subsequent Therapy for Renal Cell Carcinoma

|
By Karla Unger-Saldaña, Abdul-Hamid Bazarbachi, Tito Fojo, Alejandro Mohar
| ScienceDirect
The panel issues a strong recommendation for the use of adjuvant pembrolizumab therapy in patients with a higher risk of relapse and a weak recommendation not to treat patients with recurrence under or after initiating adjuvant pembrolizumab with a subsequent PD-1/PD-L1 ICI (Table 2). Author contributions: Jens Bedke had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Open in Who Shared Issue with article?

Cancer Interception During Treatment: Using Growth Kinetics to Create a Continuous Variable for Assessing Disease Response

|
By Mengxi Zhou, Tito Fojo, Lawrence H. Schwartz, Susan Bates
| biorxiv.org
Abstract Background: We applied 11 mathematical models of tumor growth to clinical trial data available from public and private sources. We have previously described the remarkable capacity for a simple biexponential model of tumor growth to fit thousands of datasets, and to correlate with overall survival.
Open in Who Shared Issue with article?
See all 15 articles

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Tito

Contact Tito, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified